Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase
about
A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxisN-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration.Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspectiveA comprehensive pathway map of epidermal growth factor receptor signalingNeuregulin3 alters cell fate in the epidermis and mammary glandHuman epidermal growth factor receptor signaling in acute lung injuryNuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradationCell death or survival promoted by alternative isoforms of ErbB4Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4The ErbB signaling network: receptor heterodimerization in development and cancerPI3K and Erk MAPK mediate ErbB signaling in Xenopus gastrulation.Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testisMolecular cloning and characterization of the human ErbB4 gene: identification of novel splice isoforms in the developing and adult brainThe interaction of the ErbB4 intracellular domain p80 with α-enolase in the nuclei is associated with the inhibition of the neuregulin1-dependent cell proliferation.Chemical genetics identifies small-molecule modulators of neuritogenesis involving neuregulin-1/ErbB4 signaling.Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia.Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancerOverexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.Alternative splicing in oncogenic kinases: from physiological functions to cancerFulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferationA growing family: adding mutated Erbb4 as a novel cancer targetProtein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis.Molecular mechanisms controlling the migration of striatal interneurons.Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.Biological function of nuclear receptor tyrosine kinase action.
P2860
Q22253346-119AC9E3-9C4F-43F7-A3E4-FC9D7DA3BA2FQ24535534-A2F0777C-D913-4F6D-85FC-CE225914618BQ24658389-80484677-6EE3-48C0-AE07-6886B825501EQ24672490-EBEC7E04-2410-4D07-9619-1447FA34A82BQ24681926-5B39368B-81A3-4279-AF86-D2ED68A014AFQ27002075-3CA204F3-DF96-477B-9BD6-2F65D1BF3150Q27853060-C0C7AF23-10D2-4D4A-B825-44B6EC93DD38Q28511737-D32FA475-E89E-4419-8B62-979ED0ADB088Q28593348-71CC41F0-775F-4F21-A763-814854EB4159Q28609073-908525EC-4788-4AF4-A576-E783FE16F081Q29617919-4D6FEEA8-F776-42DE-AA79-F859F5067C63Q30480771-366C3875-6000-4555-A3A5-0917231D5F85Q33403045-832660FA-10E8-497C-B11B-7AC262168FD9Q33414370-3AAAD323-407F-4E56-9174-6FC42430B095Q33631943-A5779DEB-F7A9-4089-A014-9D4EC37A89F8Q33707667-2009A4D6-22CE-44B8-BBE9-FCBDCE9B8EAEQ33760474-1CB05E6D-FEA0-468A-A58B-E3A73A1C3F45Q33863150-4BB85B1F-D042-40A7-8DC4-3C375FB692F1Q33968565-29BCD4DA-2530-440E-8C05-10FCF342B37EQ34048265-D295FBE4-EC15-452D-A711-E8D1B7734EB6Q34590284-9009B6DC-C1FD-4B91-9B5B-DA978058897DQ34613588-E6F79D3A-051A-4C05-B0E7-055133EDB1DDQ35000695-1747EDD5-45DC-49C1-807E-18A4EAF500A1Q35146683-82675762-10A2-403E-96FA-0FFCB565A767Q35228445-DD3C1FB3-84A6-45B8-9481-AC062F7A3524Q35295203-7A24604F-F5A2-466C-A912-C7A43ED69887Q35558954-4DE85531-2BEC-4541-A86C-DAA80C58FF87Q35879939-14C244FA-113F-4B12-A722-8CCAA3C8DC99Q35885511-2873396F-C605-4CE0-905C-5C19AD7C796DQ36042588-06BED072-48B0-4A93-B6A6-6CBEE76319D0Q36062442-DBC7028B-6C0D-4C16-859D-A0AD6563C0A6Q36080448-2C88B44D-3CD5-42B4-89B8-21EC70DE806EQ36095732-55D6F1D2-54B8-4061-B080-53D3032286D0Q36109287-22DF910C-D204-485D-BCAC-62FE9A563021Q36670188-3CCF3289-8DFA-45BC-BB6C-9D0D8C071E8BQ36677496-737C36A2-F306-4599-91AB-502E7809544CQ36742363-D1916F7C-E305-4411-AE66-7F7032A86E7FQ36804007-9055A594-7D67-4ADF-BA99-47993862C0F6Q36924803-36D00565-D864-4D33-9877-822FB43EA259Q36938534-F2AFAB16-F373-413A-8181-099845F27E59
P2860
Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@ast
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en-gb
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@nl
type
label
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@ast
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en-gb
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@nl
prefLabel
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@ast
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en-gb
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@nl
P2093
P356
P1433
P1476
Characterization of a naturall ...... phosphatidyl inositol 3-kinase
@en
P2093
P2888
P304
P356
10.1038/SJ.ONC.1202612
P407
P577
1999-04-22T00:00:00Z
P5875
P6179
1018058051